WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that Philip A. Downing has been promoted to Senior Vice President, Preclinical Services.
“Philip has demonstrated the ability to cultivate a strong, capable team fostered by a customer-first culture that is driving continued success in top line growth, quality standards and on time delivery. A trusted partner in client relationships, Philip's extensive experience is matched by his judgment, technical capabilities and management skills. Philip’s leadership and guidance during this time of transition for BASi has also been instrumental to the Board and me. His leadership and vision will continue to be an asset to BASi and further support our client’s drug discovery efforts,” said Larry Boulet, BASI Chairman of the Board. Mr. Downing continues to serve BASi as the acting Principal Executive Officer.
Philip has over 24 years of pharmaceutical experience in drug discovery, toxicology, non clinical and clinical research. After receiving a B.A. in Chemistry and Biology from Indiana University in 1993, Mr. Downing worked for a clinical research laboratory, GFi Pharmaceuticals (now Covance Labs), as an Analytical Scientist designing and validating radiolabeled and non-radiolabeled assays used to support clinical ADME studies. Philip has worked at BASi for nearly 20 years, starting as an Analytical Chemist and rapidly moving into influential leadership positions throughout his tenure.
This appointment continues to position BASi as the partner of choice for early-stage drug development, to enhance the Company’s ability to meet the needs of its clients and to drive future growth.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more information about BASi.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.